Technical Analysis for MYOK - MyoKardia, Inc.

Grade Last Price % Change Price Change
grade B 66.63 -0.52% -0.35
MYOK closed down 0.52 percent on Tuesday, December 10, 2019, on 53 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
See historical MYOK trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion -0.52%
Overbought Stochastic Strength -0.52%
New 52 Week Closing High Bullish -1.19%
New 52 Week High Strength -1.19%
Wide Bands Range Expansion -1.19%
Overbought Stochastic Strength -1.19%
Older signals for MYOK ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

MyoKardia, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is MYK-461, a small molecule that is in three Phase I clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy (HCM). The company also develops DCM-1, a product candidate that treats heritable dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart. In addition, it develops HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients; and LUS-1, a product candidate, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart. MyoKardia, Inc. has a strategic collaboration with Sanofi S.A. The company was founded in 2012 and is headquartered in South San Francisco, California.
Medical Specialties Anatomy Sports Medicine Cardiomyopathy Muscular System

Is MYOK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 68.6
52 Week Low 39.01
Average Volume 363,907
200-Day Moving Average 52.79
50-Day Moving Average 58.05
20-Day Moving Average 61.23
10-Day Moving Average 65.98
Average True Range 2.32
ADX 28.39
+DI 30.86
-DI 13.95
Chandelier Exit (Long, 3 ATRs ) 61.64
Chandelier Exit (Short, 3 ATRs ) 58.10
Upper Bollinger Band 71.87
Lower Bollinger Band 50.59
Percent B (%b) 0.75
BandWidth 34.75
MACD Line 2.89
MACD Signal Line 2.41
MACD Histogram 0.4798
Fundamentals Value
Market Cap 2.1 Billion
Num Shares 31.5 Million
EPS -0.65
Price-to-Earnings (P/E) Ratio -102.51
Price-to-Sales 26.88
Price-to-Book 9.37
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 68.31
Resistance 3 (R3) 68.28 67.70 68.03
Resistance 2 (R2) 67.70 67.27 67.71 67.94
Resistance 1 (R1) 67.16 67.00 66.87 67.19 67.84
Pivot Point 66.58 66.58 66.43 66.59 66.58
Support 1 (S1) 66.04 66.15 65.75 66.07 65.42
Support 2 (S2) 65.46 65.88 65.47 65.32
Support 3 (S3) 64.92 65.46 65.23
Support 4 (S4) 64.95